NCT05659654View on ClinicalTrials.gov

The Application of Ursodeoxycholic Acid for the Prevention of SARS-CoV-2 Infection (COVID-19)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

December 16, 2022

Primary Completion Date

March 3, 2023

Study Completion Date

March 8, 2023

Conditions
COVID-19
Interventions
DRUG

Ursodeoxycholic acid

250 mg/capsule, 2 capsules per day, for 4 weeks

Trial Locations (1)

300020

Chinese Academy of Medical Science and Blood Disease Hospital,CAMS & PUMC, Tianjin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER